<DOC>
	<DOC>NCT00399204</DOC>
	<brief_summary>The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin</brief_summary>
	<brief_title>Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 2560 years. 2. Ready to give written informed consent 1. Presence of ketonuria 2. Severe concurrent, infection or illness 3. History of hypersensitivity to any study drug 4. Impaired renal function 5. Pulmonary insufficiency with hypoxemia 6. Severe hepatic disease 7. Congestive heart failure 8. History of myocardial infarction or angina(stable/unstable) 9. History of alcohol or drug abuse 10. Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>